Press releases

Guard Therapeutics (publ) today announced favorable efficacy results from additional analyses of the Phase 2a AKITA study with the investigational drug candidate RMC-035. The previously reported primary results demonstrated a robust improvement in kidney function following open-heart surgery. The new analyses strengthen these findings and...

Guard Therapeutics (publ) today announced that the last patient in its ongoing Phase 2b clinical trial, POINTER, has successfully completed the final scheduled follow-up visit 90 days after surgery (last patient last visit). The study is evaluating the company’s drug candidate, RMC-035, as a kidney-protective treatment for patients undergoing...

Guard Therapeutics (publ) today announced that additional results from the Phase 2 AKITA study with the company’s drug candidate RMC-035 will be presented at the scientific conference Kidney Week 2025 organized by the American Society of Nephrology (ASN), in Houston, TX, USA. The new results are based on post hoc analyses of the previously...

Guard Therapeutics (publ) today announced that the company will present at the following investor conferences ahead of the upcoming readout of the Phase 2b POINTER study:

The quarter marked a key milestone with the completion of patient recruitment for our Phase 2b POINTER study – ahead of schedule. The positive final safety review reinforces confidence in the trial, underscoring strong momentum and positioning us well for future value creation.